4D Molecular Therapeutics (FDMT) Depreciation & Amortization (CF) (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $1.3 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.3 million, up 20.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.9 million (up 8.41% YoY), and the FY2025 annual result was $4.7 million, up 0.88% from the prior year.
• Depreciation & Amortization (CF) rose to $1.3 million in Q1 2026 per FDMT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.3 million in Q1 2026 and troughed at $406000.0 in Q1 2022.
• A 5-year average of $1.0 million and a median of $1.1 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) soared 160.0% in 2022, then decreased 10.4% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.0 million in 2022, then climbed by 8.68% to $1.1 million in 2023, then retreated by 0.54% to $1.1 million in 2024, then climbed by 10.95% to $1.2 million in 2025, then climbed by 4.36% to $1.3 million in 2026.
• Business Quant data shows FDMT's Depreciation & Amortization (CF) at $1.3 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.